menu
    • menu
    [{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ASKB589","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Phase III","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ASKB589","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ASKG315","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ASKG315","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ASKG915","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ASKG712","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ASKG712","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"AskGene Pharma Inc \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ASKG712","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AskGene Pharma Inc \/ AskGene Pharma Inc","highestDevelopmentStatusID":"6","companyTruncated":"AskGene Pharma Inc \/ AskGene Pharma Inc"},{"orgOrder":0,"company":"AskGene Pharma Inc","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AskGene Pharma Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AskGene Pharma Inc \/ AskGene Pharma Inc","highestDevelopmentStatusID":"3","companyTruncated":"AskGene Pharma Inc \/ AskGene Pharma Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by AskGene Pharma Inc

    Menu

    AskGene Pharma Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKB589

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarci...

                            Details : ASKB589 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroesophageal Junction Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : ASKB589

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKG712

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ASKG712 in Patients With Diabetic Macular Edema

                            Details : ASKG712 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Macular Edema.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 11, 2023

                            Lead Product(s) : ASKG712

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKG915

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

                            Details : ASKG915 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 22, 2023

                            Lead Product(s) : ASKG915

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKB589

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.

                            Details : ASKB589 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 01, 2022

                            Lead Product(s) : ASKB589

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKG315

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ASKG315 in Patients With Advanced Solid Tumors.

                            Details : ASKG315 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 26, 2022

                            Lead Product(s) : ASKG315

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKG315

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors

                            Details : ASKG315 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 22, 2022

                            Lead Product(s) : ASKG315

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKG712

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

                            Details : ASKG712 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Wet Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 13, 2022

                            Lead Product(s) : ASKG712

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Aosaikang Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKG712

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Recipient : AffaMed Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Diseas...

                            Details : In pre-clinical studies, AM712 (ASKG712) demonstrated robust efficacy, good ocular pharmacokinetics, and the desired safety profile supporting clinical exploration. AM712 is a novel bispecific biologic molecule specifically designed for ocular use.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 30, 2022

                            Lead Product(s) : ASKG712

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Recipient : AffaMed Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            AskGene Pharma Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : GenScript ProBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GenScript ProBio and AskGene Enter into a Non-exclusive License of A sdAb Targeting Immune Checkpoint Target

                            Details : The single-domain antibodies involved in this license agreement will be paired with AskGene's proprietary next-generation cytokine therapeutics for cancer immunotherapy and other applications.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : GenScript ProBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth